Eve Denton

Eve Denton

Auto-generated profile, based on publicly available information

Eve Denton

Asthma, Allergy and Clinical Immunology, Respiratory Medicine Alfred Hospital Melbourne Victoria Australia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
LLLuis Pérez Pérez de Llano
Luis Pérez Pérez de Llano
GSGhislaine Scelo
Ghislaine Scelo
TTTrung N. Tran
Trung N. Tran
TLTham T. Le
Tham T. Le
MFMalin Fagerås
Malin Fagerås
DPDavid B. Price
David B. Price
Rationale: There is no consensus on criteria to include in an asthma remission definition in real life. Factors associated with achieving remission after biologic initiation remain poorly understood. Objectives: To quantify the proportion of adults with severe asthma achieving multidomain-defined remission after biologic initiation and identify prebiologic characteristics associated with achieving remission that may be used to predict it. Methods: This was a longitudinal cohort study using data from 23 countries from the International Severe Asthma Registry. Four asthma outcome domains were assessed in the 1 year before and after biologic initiation. A priori–defined remission cutoffs were: 0 exacerbations/yr, no long-term oral corticosteroid (LTOCS), partly/well-controlled asthma, and percent predicted FEV1 ⩾ 80%. Remission was defined using two (exacerbations + LTOCS), three (+control or +lung function), and four of these domains. The association between prebiologic characteristics and postbiologic remission was assessed by multivariable analysis. Measurements and Main Results: A total of 50.2%, 33.5%, 25.8%, and 20.3% of patients met criteria for two-, three- (+control), three- (+lung function), and four-domain remission, respectively. The odds of achieving four-domain remission decreased by 15% for every additional 10 years of asthma duration (odds ratio, 0.85; 95% confidence interval, 0.73–1.00). The odds of remission increased in those with fewer exacerbations per year, lower LTOCS daily dose, better control, and better lung function before biologic initiation. Conclusions: One in five patients achieved four-domain remission within 1 year of biologic initiation. Patients with less severe impairment and shorter asthma duration at initiation had a greater chance of achieving remission after biologic treatment, indicating that biologic treatment should not be delayed if remission is the goal.

1 July 2021 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Open access
EDEve Denton
Eve Denton
DPDavid B. Price
David B. Price
TTTrung N. Tran
Trung N. Tran
GCG. Walter Canonica
G. Walter Canonica
AMAndrew Menzies-Gow
Andrew Menzies-Gow
MHMark Hew
Mark Hew
Allergy, eosinophilic inflammation, and epithelial dysregulation are implicated in severe asthma pathogenesis. We characterized biomarker expression in adults with severe asthma. Within the International Severe Asthma Registry (ISAR), we analyzed data from 10 countries in North America, Europe and Asia, with pre-specified thresholds for biomarker positivity (serum IgE ≥75kU/L, blood eosinophils ≥300 cells/uL, and FeNO ≥25ppb), and with hierarchical cluster analysis using biomarkers as continuous variables. Of 1,175 patients; 64% were female, age (mean ±SD) 53±15 years, body mass index (BMI) 30±8, post-bronchodilator FEV1 predicted 74±20%. By pre-specified thresholds, 59% were IgE positive, 57% eosinophil positive, and 58% FeNO positive. There was substantial inflammatory biomarker overlap; 59% were positive for either two or three biomarkers. Five distinct clusters were identified: Cluster 1 (61%, low-to-medium biomarkers) comprised highly symptomatic, older females with elevated BMI and frequent exacerbations; Cluster 2 (18%, elevated eosinophils and FeNO) older females with lower BMI and frequent exacerbations; Cluster 3 (14%, extremely high FeNO) older, highly symptomatic, lower BMI and preserved lung function; Cluster 4 (6%, extremely high IgE) younger, long duration of asthma, elevated BMI, and poor lung function; Cluster 5 (1.2%, extremely high eosinophils) younger males with low BMI, poor lung function, and high burden of sino-nasal disease and polyposis. There is significant overlap of biomarker positivity in severe asthma. Distinct clusters according to biomarker expression exhibit unique clinical characteristics, suggesting the occurrence of discrete patterns of underlying inflammatory pathway activation and providing pathogenic insights relevant to the era of monoclonal biologics.

1 May 2019 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Open access
EDEve Denton
Eve Denton
JBJanet Bondarenko
Janet Bondarenko
TTTunnRen Tay
TunnRen Tay
JLJoy Lee
Joy Lee
NRNaghmeh Radhakrishna
Naghmeh Radhakrishna
MHMark Hew
Mark Hew
Understanding of dysfunctional breathing in patients with difficult asthma who remain symptomatic despite maximal inhaler therapy is limited. We characterized the pattern of dysfunctional breathing in patients with difficult asthma and identified possible contributory factors. Dysfunctional breathing was identified in patients with difficult asthma using the Nijmegen Questionnaire (score >23). Demographic characteristics, asthma variables, and comorbidities were assessed. Multivariate logistic regression was performed for dysfunctional breathing, adjusted for age, sex, body mass index, and airflow obstruction. Of 157 patients with difficult asthma, 73 (47%) had dysfunctional breathing. Compared with patients without dysfunctional breathing, those with dysfunctional breathing experienced poorer asthma status (symptom control, quality of life, and exacerbation rates) and greater unemployment. In addition, more frequently they had elevated sino-nasal outcome test scores, anxiety, depression, sleep apnea, and gastroesophageal reflux. On multivariate analysis, anxiety (odds ratio [OR], 3.26; 95% CI, 1.18-9.01; P = .02), depression (OR, 2.8; 95% CI, 1.14-6.9; P = .03), and 22-item sino-nasal outcome test score (OR, 1.03; 95% CI, 1.003-1.05; P = .03) were independent risk factors for dysfunctional breathing. Dysfunctional breathing is common in difficult asthma and associated with worse asthma status and unemployment. The independent association with psychological disorders and nasal obstruction highlight an important interaction between comorbid treatable traits in difficult asthma.

1 March 2016 in Journal of Multidisciplinary Healthcare
Verified
Journal Article
Open access
PDF file
MCMatthew Conron
Matthew Conron
EDEve Denton
Eve Denton
Lung cancer is a major worldwide health burden, with high disease-related morbidity and mortality. Unlike other major cancers, there has been little improvement in lung cancer outcomes over the past few decades, and survival remains disturbingly low. Multidisciplinary care is the cornerstone of lung cancer treatment in the developed world, despite a relative lack of evidence that this model of care improves outcomes. In this article, the available literature concerning the impact of multidisciplinary care on key measures of lung cancer outcomes is reviewed. This includes the limited observational data supporting improved survival with multidisciplinary care. The impact of multidisciplinary care on other benchmark measures of quality lung cancer treatment is also examined, including staging accuracy, access to diagnostic investigations, improvements in clinical decision making, better utilization of radiotherapy and palliative care services, and improved quality of life for patients. Health service research suggests that multidisciplinary care improves care coordination, leading to a better patient experience, and reduces variation in care, a problem in lung cancer management that has been identified worldwide. Furthermore, evidence suggests that the multidisciplinary model of care overcomes barriers to treatment, promotes standardized treatment through adherence to guidelines, and allows audit of clinical services and for these reasons is more likely to provide quality care for lung cancer patients. While there is strengthening evidence suggesting that the multidisciplinary model of care contributes to improvements in lung cancer outcomes, more quality studies are needed.

1 May 2020 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
EDEve Denton
Eve Denton
JLJoy Lee
Joy Lee
TTTunnRen Tay
TunnRen Tay
NRNaghmeh Radhakrishna
Naghmeh Radhakrishna
FHFiona Hore-Lacy
Fiona Hore-Lacy
MHMark Hew
Mark Hew

22 June 2024 in Allergy
Verified
Journal Article
Open access
EDEve Denton
Eve Denton
MHMark Hew
Mark Hew
MPMatthew Peters
Matthew Peters
JUJohn W. Upham
John W. Upham
LBLakmini Bulathsinhala
Lakmini Bulathsinhala
DPDavid B. Price
David B. Price
Background: Biologic asthma therapies reduce exacerbations and long‐term oral corticosteroids (LTOCS) use in randomized controlled trials (RCTs); however, there are limited data on outcomes among patients ineligible for RCTs. Hence, we investigated responsiveness to biologics in a real‐world population of adults with severe asthma. Methods: Adults in the International Severe Asthma Registry (ISAR) with ≥24 weeks of follow‐up were grouped into those who did, or did not, initiate biologics (anti‐IgE, anti‐IL5/IL5R, anti‐IL4/13). Treatment responses were examined across four domains: forced expiratory volume in 1 second (FEV 1 ) increase by ≥100 mL, improved asthma control, annualized exacerbation rate (AER) reduction ≥50%, and any LTOCS dose reduction. Super‐response criteria were: FEV 1 increase by ≥500 mL, new well‐controlled asthma, no exacerbations, and LTOCS cessation or tapering to ≤5 mg/day. Results: 5.3% of ISAR patients met basic RCT inclusion criteria; 2116/8451 started biologics. Biologic initiators had worse baseline impairment than non‐initiators, despite having similar biomarker levels. Half or more of initiators had treatment responses: 59% AER reduction, 54% FEV 1 increase, 49% improved control, 49% reduced LTOCS, of which 32%, 19%, 30%, and 39%, respectively, were super‐responses. Responses/super‐responses were more frequent in biologic initiators than in non‐initiators; nevertheless, ~40–50% of initiators did not meet response criteria. Conclusions: Most patients with severe asthma are ineligible for RCTs of biologic therapies. Biologics are initiated in patients who have worse baseline impairments than non‐initiators despite similar biomarker levels. Although biologic initiators exhibited clinical responses and super‐responses in all outcome domains, 40–50% did not meet the response criteria.